The utility of sildenafil in pulmonary hypertension: A focus on bronchopulmonary dysplasia

Archives of Disease in Childhood

Volumn 98, Issue 8, 2013, Pages 613-617

  Wardle, Andrew James ^a   Wardle, Richard ^b   Luyt, Karen ^a   Tulloh, Robert ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; CYTOCHROME P450; ILOPROST; SILDENAFIL;

ANTIHYPERTENSIVE THERAPY; COUGHING; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOTENSION; LUNG ARTERY PRESSURE; LUNG DYSPLASIA; LUNG VASCULAR RESISTANCE; MIGRAINE; MONOTHERAPY; OUTCOME ASSESSMENT; OXYGEN THERAPY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SLEEP DISORDER; SURVIVAL; THERAPY EFFECT;

BRONCHOPULMONARY DYSPLASIA; PAEDIATRIC; PULMONARY HYPERTENSION; RESPIRATORY; SILDENAFIL;

BRONCHOPULMONARY DYSPLASIA; HUMANS; HYPERTENSION, PULMONARY; INFANT, NEWBORN; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; SULFONES; TREATMENT OUTCOME;

EID: 84881244043     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/archdischild-2012-303333     Document Type: Review

References (40)

1. Greenough A. Long-term pulmonary outcome in the preterm infant. Neonatology 2008;93:324-7.
2. Hentschel J, Berger TM, Tschopp A, et al. Population-based study of bronchopulmonary dysplasia in very low birth weight infants in Switzerland. Eur J Pediatr 2005;164:292-7.
3. Khemani E, McElhinney DB, Rhein L, et al. Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era. Pediatrics 2007;120:1260-9.
4. Northway WH Jr, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med 1967;276:357-68.
5. Shennan AT, Dunn M, Ohlsson A, et al. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirements in the neonatal period. Pediatrics 1988;82:527-32.
6. Jobe AH, Bancalari E. Bronchopulmonary Dysplasia. Am J Respir Crit Med 2001;163:1723-9.
7. Stevenson DK, Wright LL, Lemons JA, et al. Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Research Network, January 1993-December 1994. Am J Obstet Gynecol 1998;179:1632-9.
8. Abman SH. Monitoring cardiovascular function in infants with chronic lung disease of prematurity. Arch Dis Child 2002;87:F15-18.
9. An HS, Bae EJ, Kim GB, et al. Pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. Korean Circ J 2010; 40: 131-6.
10. Berger R, Beghetti M, Humpl T, et al. Clinical features of paediatric pulmonary hypertension: a registry study. Lancet 2012;379:537-46.
11. Haworth SG. The management of pulmonary hypertension in children. Arch Dis Child 2008;93:620-5.
12. Gibbs J. Recommendations on the management of pulmonary hypertension in clinical practice. Heart 2001;86:1-13.
13. Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54(Suppl 1):S55-66.
14. Slaughter JL, Pakrashi T, Jones DE, et al. Echocardiography detection of pulmonary hypertension in extremely low birth weight infants with bronchopulmonary dysplasia requiring prolonged positive pressure ventilation. J Perinatol 2011;31:635-40.
15. Nyp M, Sandritter T, Poppinga N, et al. Sildenafil citrate, bronchopulmonary dysplasia and disordered pulmonary gas exchange: any benefits? J Perinatol 2012;32:64-9.
16. Mourani P, Sontag M, Ivy D, et al. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr 2009;154:379-84.
17. Wardle AJ, Tulloh RM. Evolving management of pediatric pulmonary arterial hypertension: impact of phosphodiesterase inhibitors. Pediatr Cardiol 2013; 34:213-19.
18. Wardle AJ, Wardle R, Luyt K, et al. Paediatric pulmonary hypertension and sildenafil: current practice and controversies. Arch Dis Child 2013 (In press).
19. Abman SH, Chatfield BA, Hall SL, et al. Role of endothelium-derived relaxing factor during transition of pulmonary circulation at birth. Am J Physiol Heart Circ Physiol 1990;259:H1921-27.
20. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004;351:1655-65.
21. Deruelle P, Grover TR, Storme L, et al. Effects of BAY 41-2272, a soluble guanylate cyclase activator, on pulmonary vascular reactivity in the ovine fetus. Am J Physiol Lung Cell Mol Physiol 2005;288:L727-33.
22. Sun X, Z Li, Liu Y, et al. Inhibition of cGMP phosphodiesterase 5 suppresses matrix metalloproteinase-2 production in pulmonary artery smooth muscle cells. Clin Exp Pharmacol Physiol 2010;37:362-67.
23. Broughton BR, Walker BR, Resta TC. Chronic hypoxia induces Rho kinase-dependent myogenic tone in small pulmonary arteries. Am J Physiol Lung Cell Mol Physiol 2008;294:L797-806.
24. Nagendran J, Archer SL, Soliman D, et al. PDE5 is highly expressed in the hypertrophied human right ventricle and acute inhibition of PDE5 improves contractility. Circulation 2007;116:238-48.
25. Karatza AA, Bush A, Magee AG. Safety with pulmonary hypertension. Int J Cardiol 2005;100:267-73.
26. Mukherjee A, Dombi T, Wittke B, et al. Population pharmacokinetics of sildenafil in term neonates: evidence of rapid maturation of metabolic clearance in the early postnatal period. Clin Pharmacol Ther 2009;85:56-63.
27. Carroll WD, Dhillon R. Sildenafil as a treatment for pulmonary hypertension. Arch Dis Child 2003;88:827-8.
28. Michelakis ED, Tymchak W, Noga M. Long term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003;108:2066-9.
29. Meau-Petit V, Thouvenin G, Meau-Petit V, et al. Bronchopulmonary dysplasia-associated pulmonary arterial hypertension of very preterm infants. Arch Pediatr 2013;20:44-53.
30. BNF for children. 2012. http://www.bnf.org/bnf/index.htm (accessed 8 Jun 2012).
31. Cordell WH, Maturi RK, Costigan TM, et al. Retinal effects of 6 months of daily use of tadalafil or sildenafil. Arch Ophthalmol 2009;127:367-73.
32. Fang AY, Guy KJ, König K. The effect of sildenafil on retinopathy of prematurity in very preterm infants. J Perinatol 2013;33:218-21.
33. Barst RJ, Ivy DD, Gaitan G, et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naïve children with pulmonary arterial hypertension. Circulation 2012;125:324-34.
34. U.S Food and Drug Administration. FDA Drug Safety Communication: FDA recommends against use of Revatio in children with pulmonary hypertension. 2012. http://www.fda.gov/Drugs/DrugSafety/ucm317123.htm (accessed 11 Mar 2012).
35. Caputo S, Furcolo G, Rabuano R, et al. Severe pulmonary arterial hypertension in a very premature baby with bronchopulmonary dysplasia: normalization with long-term sildenafil. J Cardiovasc Med (Hagerstown) 2010;11:704-6.
36. Maiya S, Hislop AA, Flynn Y, et al. Response to bosentan in children with pulmonary hypertension. Heart 2006;92:664-70.
37. Krishnan U, Krishnan S, Gewitz M. Treatment of pulmonary hypertension in children with chronic lung disease with newer oral therapies. Pediatr Cardiol 2008;29:1082-86.
38. Gürakan B, Kayiran P, Öztürk N, et al. Therapeutic combination of sildenafil and iloprost in a preterm neonate with pulmonary hypertension. Pediatr Pulmonol 2011;46:617-20.
39. Shah PS, Ohlsson A. Sildenafil for pulmonary hypertension in neonates. Cochrane Database Syst Rev 2011;8:CD005494. doi: 10.1002/14651858.CD005494.pub3.
40. König K, Barfield C, Andersen C. The effect of sildenafil in preterm infants with evolving chronic lung disease (SPICE trial): a pilot study. Australia: Mercy Hospital for Women. http://clinicaltrials.gov/ct2/show/ NCT00431418http://clinicaltrials.gov/ ct2/show/NCT00431418 (accessed 10 Jul 2012).